by The newborn calf serum market has been gaining traction over the years. Newborn calf serum is serum derived from blood collected from calf that is less than 20 days old. It finds wide application in cell culture media for growth of various cell lines owing to the availability of growth promoting proteins. It also contains hydrolytic enzymes, attachment and spreading factors, nucleotides, vitamins, and minerals required for optimal cell growth. Rising need for cell culture in various applications including vaccine development, biopharmaceuticals production, consumer goods testing, and others has spurred the demand for newborn calf serum.
The Global Newborn Calf Serum Market is estimated to be valued at US$ 273.39 Bn in 2024 and is expected to exhibit a CAGR of 9.9% over the forecast period 2024 to 2031.
Key players operating in the newborn calf serum market are Tactile Medical, Bio Compression Systems, Essity Medical Solutions, Sigvaris Group, Lohmann & Rauscher, Mego Afek, ThermoTek, Medi GmbH, Compressel, Huntleigh Healthcare, JUZO, Bio Horizons, medi UK, ArjoHuntleigh, BSN Medical, Lympha Press, Paul Hartmann, Convatec, Herantis Pharma.
Key Takeaways
Key players operating in the newborn calf serum are Tactile Medical, Bio Compression Systems, Essity Medical Solutions, Sigvaris Group, Lohmann & Rauscher, Mego Afek, ThermoTek, Medi GmbH, Compressel, Huntleigh Healthcare, JUZO, Bio Horizons, medi UK, ArjoHuntleigh, BSN Medical, Lympha Press, Paul Hartmann, Convatec, Herantis Pharma. The rising investments in cell culture, vaccines, and biopharmaceutical research has ignited demand for Newborn Calf Serum Market Trends. With growing disease incidence, the need for new treatment development is surging and thus driving the newborn calf serum market.
The global newborn calf serum market is anticipated to grow at an accelerated pace owing to expanding biopharmaceutical industry worldwide. North America dominated the market in 2024 owing to strategic presence of global key players and rising biologics R&D. Asia Pacific is expected to witness highest growth during the forecast period with growing biotech space in China, India, and South Korea. Latin America and Middle East & Africa also offer lucrative opportunities for newborn calf serum providers.
Market Key Trends
Steady rise in cell culture practices is a key trend driving the newborn calf serum market globally. Newborn calf serum is a widely preferred supplement for mesenchymal stem cell cultures owing to quality protein extracts for growth stimulation. Growing stem cell therapy research for COVID-19, cancers and genetic disorders has augmented the demand from cell culture applications. Further, continuous serum supply and standardization of calf sourcing practices by market players are also facilitating the adoption in bioproduction workstreams.
Porter’s Analysis
Threat of new entrants: Low barrier to enter as there are few patent protections for generic products and limited economies of scale. However, existing players have significant brand loyalty as they have well established distribution and supply chains.
Bargaining power of buyers: Buyers like hospitals and research labs have high bargaining power as there are many existing players. But options are limited for specialty products requiring certifications.
Bargaining power of suppliers: Suppliers of raw materials have moderate power as products require specific materials and certifications. Suppliers can thrive due to industry growth potential but depend on existing players.
Threat of new substitutes: Threat is moderate as alternative solutions exist but each has limitations. Complete substitutes are difficult as products require certification for specific applications and conditions.
Competitive rivalry: Intense competition among existing players to gain market share and benefit from industry growth. Players compete based on quality, pricing, distribution and innovation in specialty products and services.
Geographical Regions
North America is currently the largest market for newborn calf serum, accounting for over 35% of global market value due to concentration of pharmaceutical and research companies. The region is expected to continue its dominance over the forecast period supported by health infrastructure, research funding and commercialization of new drugs and therapies.
Asia Pacific region offers the fastest market growth for newborn calf serum. The market is growing at a CAGR of over 12% in Asia Pacific led by China and India due to rising healthcare expenditure, expanding medical research and increasing investments in pharmaceutical and biotech sectors.
*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it.
